Navigation Links
ACORN's Oncology-focused Contract Research Organization Exceeds Projections
Date:3/31/2008

Accelerated Community Oncology Research Network, Inc. Surpasses 2007

Outlook

MEMPHIS, Tenn., March 31 /PRNewswire/ -- The Accelerated Community Oncology Research Network, Inc. (ACORN), a national oncology clinical trial network, announced today that its Contract Research Organization (CRO) exceeded performance expectations over the past 12 months. ACORN's CRO provides the full range of research services to sponsors, from clinical trial design to site selection to the results phase with bioanalysis and findings presentation. "Sponsors have embraced the strength of ACORN CRO oncology focus. We are pleased that our activity in 2007 exceeded our projections and 1st Q 2008 appears equally impressive," remarked Steve Coplon, CEO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

Exclusively focused on oncology, ACORN CRO is backed by scientists and medical professionals dedicated to advancing cancer care through research. An important added strength resides in ACORN's network of community oncology researchers, specifically selected because of their commitment to oncology research and excellence in its execution. Close working relationships with demographically diverse US oncology practices result.

ACORN, Inc., a privately held company, significantly enhances the speed, accuracy, and productivity of conducting clinical research in the community oncology setting. Proactive project management with focused teams of clinical experts achieves these goals. Well-defined processes augmented by proprietary technology provide oversight and efficiencies on study functions for both pharma and participating sites.

Strong site relationships enable ACORN CRO to achieve enrollment targets within required timelines. Well-defined processes for site selection include comprehensive study-specific questionnaires, feasib
'/>"/>

SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
3. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
4. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
5. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
6. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
7. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
8. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
9. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
10. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
11. Low Acid Coffee Backed By Scientific Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...wswire-FirstCall/ -- , - Not for UK Journal... Products for Human Use (CHMP) today,announced it...el(R),(etanercept) as a treatment for children ag...laque psoriasis. If approved by the European,Comm...Enbrel will become the,first biologic treatment i...
(Date:11/20/2008)...Nov. 20 GlaxoSmithKline (...es Food and Drug Administration (FDA) granted acce... the treatment of thrombocytopenia in patients wit...pura (ITP) who have had an insufficient response t... The approval is a significant milestone for PROMA...
(Date:11/20/2008)...FirstCall/ -- Duska Therapeutics,Inc., (OTC Bull...mitted its,pivotal Phase 3 ATPace clinical trial ...ssment (SPA) procedure with the U.S. Food and Drug...ng an agreement with the FDA, Duska intends to ini...o-controlled and randomized Phase 3,clinical tria...
(Date:11/19/2008)... Posit Science Corporation,researcher, Dan Tinker...ce,Annual Conference in Washington, DC this week ...by Boomers. The computerized brain plasticity-bas...ises that target auditory and,language systems. ...mprovements in cognition by improving speed and ac...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Location location location important for genes too 4646 1Location location location important for genes too 4646 2VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 1VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 2Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 1Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 1Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 3Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 4
...2007 /PRNewswire/ -- Addex Pharmaceuticals,announc...proof of,concept trial with its lead compound ADX1... its primary objective, the absence of,pain at 2 h...and,also showed trends towards improvement in pain...ther time points. ADX10059 has,already recently de...
...WIRE)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasda...ase III,AIR-CF2 study evaluating aztreonam lysine ...stic fibrosis (CF) who have,pulmonary Pseudomonas ... treatment course of aztreonam lysine significantl...nous (IV) antibiotics versus,placebo. All patients...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
(Date:11/21/2008)... Nov. 21 New research a...a smokeless, spitless tobacco product aimed at you... found that RJ Reynolds, Camel Snus - touted as a ...tains surprisingly high levels of nicotine. , ...other snuff products," said Bruce Adkins of the st...
(Date:11/21/2008)...J., Nov. 21 Today, presc...ervention in treating 88 percent of patients suffe...ans treated for a chronic condition account for 96...percent of all medical costs. A proprietary new p...Health Solutions, Inc. (NYSE: MHS ) significantl...
(Date:11/21/2008)...RNewswire/ -- In a statewide survey, 33 physicians...or Surgery at Presbyterian Hospital of Dallas were...ting of " Super Doctors ." , , Each year, t...fessional Media, Inc. to survey more than 38,000 m...ask, "If you needed medical care, which doctor wou...
(Date:11/21/2008)...bacco use is more prevalent and smoking cessation ...yperactivity Disorder (A.D.H.D.) In a study of sm...ptoms, those who exhibited elevated hyperactivity ...ed lower quit rates after 8 weeks than those with ...D.H.D. symptoms. The study, now available online ...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...l technology to rapidly screen thousands of drugs ... health threats// in the United States — diabetes ...ular biology and pharmacology at Washington Univer...nd Thomas Baranski, M.D., Ph.D., professor of medi...
...al synapses, microanatomical structures similar to...the Board of Governors' Gene Therapeutics Research...firmed the existence of anatomical structures that... a T cell and its target, an antigen-presenting br...
...interest of researchers from Auckland University, ...ma in humans, after the trials// on rats proved su...rd to having a few volunteers on board to investig...served an increase in allergies like asthma with c...
...ct surgery is higher in patients who have taken al... prostate.// According to the 3 medical associati...erican Society of Cataract and Refractive Surgery ..., mentioning the use of drugs like Flomax (tamsulo...
Other Medicine News:Health News:New Company Will Seek Drugs Against Diabetes and Cancer 2Health News:New Company Will Seek Drugs Against Diabetes and Cancer 3Health News:Alpha-blockers call for modification in cataract surgery 2Health News:Alpha-blockers call for modification in cataract surgery 3
...ons stand alone. It can also be installed as part ...a management system which can be used in ophthalmi...us, retinal surgeries are supported through the mo...per charts. They are supported on tablet PC techno...
...n a powerful, easy-to-use medical practice design ...and business requirements and situations of an oph...rovide patient care assistance as well as ensure d... for Eye's simple "point and click" or touch scree...
...ion to assist you in managing your optometric prac...hrough the creative use of technology. No more nee...waiting to see the doctor. No more wasting time se... handwriting on all paperwork. Give your administr...
...c Medical Office (EMO) for the Optometry specialis...n addition to retrieving and storing your charts e...e patient office flow including documentation of p... billing information. ChartLogic also gives you da...
Medicine Products: